Investigating how lactate affects pulmonary arterial hypertension
Official title: LDHA-lactate signaling in pulmonary arterial hypertension
Funded at University of California at Davis · NIH-10993634 · Data updated 2026-11-12
This study is looking at how a substance called lactate affects the cells in the lungs of people with pulmonary arterial hypertension (PAH), with the hope of finding new ways to treat this condition and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $588,098 |
| NIH project number | 5R01HL172488-02 |
| Project ID | NIH-10993634 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
✕Less likely to help
Patients with other forms of pulmonary hypertension or those without a diagnosis of pulmonary arterial hypertension may not benefit from this research.
What this research studies
This research focuses on pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs that can lead to heart failure. The study aims to understand how lactate, a byproduct of metabolism, influences the behavior of cells in the pulmonary arteries, particularly how it promotes cell growth and resistance to cell death. By examining the mechanisms behind this process, the research seeks to identify potential therapeutic targets that could help manage or treat PAH. Patients may benefit from insights that could lead to new treatments aimed at reducing the progression of this disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or reverse the progression of pulmonary arterial hypertension.
How similar studies have gone: Other research has shown promising results in targeting metabolic pathways in similar conditions, suggesting that this approach could be effective.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Goncharova, Elena — University of California at Davis
- Study coordinator: Goncharova, Elena
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.